Literature DB >> 31497206

DHX9 inhibits epithelial-mesenchymal transition in human lung adenocarcinoma cells by regulating STAT3.

Xueli Yan1, Jing Chang1, Ruiying Sun1, Xia Meng1, Wei Wang1, Lizhong Zeng1, Boxuan Liu1, Wei Li1, Xuehua Yan2, Chen Huang3, Yongxi Zhao4, Zongfang Li5, Shuanying Yang1.   

Abstract

DHX9 has numerous functions regulating transcription, translation, RNA processing and transport, and DNA replication and maintenance of genomic stability. It is involved in human cancers as either an oncogene or tumor suppressor. However, its role in the progression of lung cancer and underlying mechanisms remains unclear. In this study, we demonstrated that DHX9 is overexpressed in human lung cancer tissues and serum. Also, a favorable prognosis of lung adenocarcinoma is predicted when DHX9 is at a high level. DHX9 knockdown promoted cell proliferation, migration, and invasion and inhibited apoptosis progression in A549 cells. Moreover, DHX9 knockdown led to a significant decrease of E-cadherin expression, an increase of vimentin and snail, and a significant increase in the phosphorylation of STAT3 in A549 cells. In summary, our studies identified a novel role of DHX9 in driving tumor growth and epithelial-mesenchymal transition progress of A549 cells. We propose that the STAT3 pathway may be implicated in the DHX9-related epithelial-mesenchymal transition of lung adenocarcinoma. Therefore, DHX9 may be a prognostic marker or potential therapeutic target for lung adenocarcinoma.

Entities:  

Keywords:  DHX9; EMT; Lung adenocarcinoma; STAT3

Year:  2019        PMID: 31497206      PMCID: PMC6731401     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  36 in total

1.  Coordination of editing and splicing of glutamate receptor pre-mRNA.

Authors:  Eva Bratt; Marie Ohman
Journal:  RNA       Date:  2003-03       Impact factor: 4.942

Review 2.  Epithelial-mesenchymal transitions in development and pathologies.

Authors:  Jean Paul Thiery
Journal:  Curr Opin Cell Biol       Date:  2003-12       Impact factor: 8.382

3.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.

Authors:  Margit A Huber; Ninel Azoitei; Bernd Baumann; Stefan Grünert; Andreas Sommer; Hubert Pehamberger; Norbert Kraut; Hartmut Beug; Thomas Wirth
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

4.  RNA helicase A is necessary for translation of selected messenger RNAs.

Authors:  Tiffiney Roberts Hartman; Shuiming Qian; Cheryl Bolinger; Soledad Fernandez; Daniel R Schoenberg; Kathleen Boris-Lawrie
Journal:  Nat Struct Mol Biol       Date:  2006-05-07       Impact factor: 15.369

5.  Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells.

Authors:  Brian P Schlegel; Lea M Starita; Jeffrey D Parvin
Journal:  Oncogene       Date:  2003-02-20       Impact factor: 9.867

6.  Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter.

Authors:  S Myöhänen; S B Baylin
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

7.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.

Authors:  Christopher D Scharer; Colleen D McCabe; Mohamed Ali-Seyed; Michael F Berger; Martha L Bulyk; Carlos S Moreno
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator.

Authors:  Toshifumi Tetsuka; Hiroaki Uranishi; Takaomi Sanda; Kaori Asamitsu; Jiang-Ping Yang; Flossie Wong-Staal; Takashi Okamoto
Journal:  Eur J Biochem       Date:  2004-09

9.  Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines.

Authors:  Cinzia Zucchini; Anna Rocchi; Maria Cristina Manara; Paola De Sanctis; Cristina Capanni; Michele Bianchini; Paolo Carinci; Katia Scotlandi; Luisa Valvassori
Journal:  Int J Oncol       Date:  2008-01       Impact factor: 5.650

Review 10.  E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer.

Authors:  Otto Schmalhofer; Simone Brabletz; Thomas Brabletz
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

View more
  7 in total

1.  The G4 Resolvase DHX36 Possesses a Prognosis Significance and Exerts Tumour Suppressing Function Through Multiple Causal Regulations in Non-Small Cell Lung Cancer.

Authors:  Yuxin Cui; Zhilei Li; Junxia Cao; Jane Lane; Emily Birkin; Xuefei Dong; Lijian Zhang; Wen G Jiang
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 2.  The enigmatic helicase DHX9 and its association with the hallmarks of cancer.

Authors:  Chloe Gulliver; Ralf Hoffmann; George S Baillie
Journal:  Future Sci OA       Date:  2020-11-02

3.  A STING-related prognostic score predicts high-risk patients of colorectal cancer and provides insights into immunotherapy.

Authors:  Si-Yuan Chen; Siyu Chen; Wanjing Feng; Ziteng Li; Yixiao Luo; Xiaodong Zhu
Journal:  Ann Transl Med       Date:  2021-01

Review 4.  Epithelial-mesenchymal transition and its transcription factors.

Authors:  Pallabi Debnath; Rohit Singh Huirem; Paloma Dutta; Santanu Palchaudhuri
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

5.  MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.

Authors:  Yang Liu; Siyuan Xu; Ying Huang; Shaoyan Liu; Zhengang Xu; Minghui Wei; Jie Liu
Journal:  Int J Biol Sci       Date:  2021-08-03       Impact factor: 6.580

6.  High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma.

Authors:  Feng Shi; Shengli Cao; Yaohua Zhu; Qiwen Yu; Wenzhi Guo; Shuijun Zhang
Journal:  J Clin Lab Anal       Date:  2021-10-22       Impact factor: 2.352

Review 7.  DNA and RNA Binding Proteins: From Motifs to Roles in Cancer.

Authors:  Ondrej Bonczek; Lixiao Wang; Sivakumar Vadivel Gnanasundram; Sa Chen; Lucia Haronikova; Filip Zavadil-Kokas; Borivoj Vojtesek
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.